ADC Therapeutics (ADCT) awards 62,900 RSU shares to chief accounting officer

Rhea-AI Filing Summary

ADC Therapeutics SA reported that Chief Accounting Officer Lisa Michelle Kallebo received a grant of 62,900 Common Shares on February 13, 2026 as a restricted share unit award valued at $3.99 per share. These shares vest in three equal installments: one-third on the first anniversary of the grant date and one-third on each of the following two anniversaries, subject to continued service. On the same date, 5,433 Common Shares were withheld by the company at $3.99 per share to cover her tax obligations from previously vesting restricted share units. After these transactions, she directly owned 128,224 Common Shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kallebo Lisa Michelle

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	62,900	$3.99	$251K
Tax Withholding	Common Shares	5,433	$3.99	$22K

Holdings After Transaction: Common Shares — 133,657 shares (Direct)

Footnotes (1)

1. Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kallebo Lisa Michelle

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NJ 07974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/13/2026		A		62,900(1)	A	$3.99	133,657	D
Common Shares	02/13/2026		F		5,433(2)	D	$3.99	128,224	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event.

2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ADC Therapeutics (ADCT) disclose about Lisa Michelle Kallebo’s equity grant?

ADC Therapeutics granted Lisa Michelle Kallebo 62,900 Common Shares as a restricted share unit award at $3.99 per share. The award vests in three equal annual installments starting one year after the February 13, 2026 grant date, contingent on continued service.

How do the new restricted share units for ADCT’s Chief Accounting Officer vest over time?

The 62,900 restricted share units granted to ADCT’s Chief Accounting Officer vest one-third on the first anniversary of the February 13, 2026 grant date. The remaining two-thirds vest in equal one-third portions on each subsequent anniversary, assuming she continues in service.

Why were 5,433 ADC Therapeutics shares disposed of in this Form 4 filing?

The 5,433 Common Shares shown as a disposition were withheld by ADC Therapeutics at $3.99 per share to satisfy Lisa Michelle Kallebo’s tax withholding obligations arising from previously granted restricted share units that vested, rather than being an open-market sale.

What is Lisa Michelle Kallebo’s total direct share ownership in ADCT after these transactions?

Following the grant and tax-withholding transactions, Lisa Michelle Kallebo directly owns 128,224 Common Shares of ADC Therapeutics. This figure reflects both the award of 62,900 shares and the withholding of 5,433 shares to cover tax obligations.

Does the ADCT Form 4 indicate open-market buying or selling by the Chief Accounting Officer?

No open-market trades are indicated. The Form 4 shows a grant of 62,900 restricted share units and a tax-withholding disposition of 5,433 shares, where the issuer withheld shares to cover tax obligations from previously vesting equity awards.